Pharmabiz

Bristol announces positive results from phase 3 CheckMate -648 trial of Opdivo plus chemotherapy & Opdivo plus Yervoy to treat unresectable advanced or metastatic ESCC

Bristol Myers Squibb announced positive topline results from the phase 3 CheckMate -648 trial evaluating treatment with Opdivo (nivolumab) plus chemotherapy or Opdivo plus Yervoy (ipilimumab) in ...
Monthly Prescribing Reference

Opdivo-Based Regimens Approved as First-Line Treatments for Esophageal Cancer

Swallowable sampling device combined with methylation biomarker panel IDs Barrett esophagus. The approvals are based on data from the phase 3 CheckMate-648 trial, which included 970 adults with ...
Pharmabiz

BMS announces positive results from phase 3 CheckMate -9LA trial of Opdivo plus Yervoy with two cycles of chemotherapy for patients with metastatic NSCLC

Bristol Myers Squibb (BMS) announced four-year follow-up results from the phase 3 CheckMate -9LA trial demonstrating durable, long-term survival benefits with Opdivo (nivolumab) plus Yervoy ...